Black Diamond Therapeutics Inc Ordinary Shares BDTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.81
- Day Range
- $1.78–1.87
- 52-Week Range
- $1.60–4.94
- Bid/Ask
- $1.78 / $1.83
- Shares Outstanding
- 57.30M
- Market Cap
- $102.57M
- Volume/Avg
- 708,209 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 3.81
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
Valuation
|
Metric
|
BDTX
|
|---|---|
Price/Earnings (Normalized) | 3.81 |
Price/Book Value | 0.98 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BDTX
Financial Strength
|
Metric
|
BDTX
|
|---|---|
Quick Ratio | 8.14 |
Current Ratio | 8.46 |
Interest Coverage | — |
Quick Ratio
BDTX
Profitability
|
Metric
|
BDTX
|
|---|---|
Return on Assets (Normalized) | −14.27% |
Return on Equity (Normalized) | −17.96% |
Return on Invested Capital (Normalized) | −18.62% |
Return on Assets
BDTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>Jlf&WT | LOCK|!%%VT | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$zy<#@ | LOCK|Q&<% | $71B | |||
| argenx SE ADR
ARGX
| LOCK|Kz%#zd | LOCK|sZC | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pm$<@xX | LOCK|@! | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hbJtwQ? | LOCK|^#s?j | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gbpgRKZ | LOCK|$pG?m | $26B | |||
| Moderna Inc
MRNA
| LOCK|Sx%nCC | LOCK|@j | $25B | |||
| Incyte Corp
INCY
| LOCK|&qcL<w | LOCK|@& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|pg#zXW | LOCK|QCd | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$<WS&f | LOCK|q<f | $16B |
United States